Pfizer-Valneva Lyme Vaccine Shows Strong Efficacy, Misses Key Goal

Pfizer and Valneva announced their Lyme disease vaccine demonstrated over 70% efficacy in trials, though it missed a specific goal, potentially complicating its regulatory approval process.